LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,614
تعداد دریافت فایل اصل مقاله11,291,420
Shokripour, Mansoureh, Hosseini, Seyed Ehsan, Omidifar, Navid, Mokhtari, Maral, Safaei, Akbar. (1402). Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran. سامانه مدیریت نشریات علمی, 49(2), 77-87. doi: 10.30476/ijms.2023.96892.2855
Mansoureh Shokripour; Seyed Ehsan Hosseini; Navid Omidifar; Maral Mokhtari; Akbar Safaei. "Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran". سامانه مدیریت نشریات علمی, 49, 2, 1402, 77-87. doi: 10.30476/ijms.2023.96892.2855
Shokripour, Mansoureh, Hosseini, Seyed Ehsan, Omidifar, Navid, Mokhtari, Maral, Safaei, Akbar. (1402). 'Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran', سامانه مدیریت نشریات علمی, 49(2), pp. 77-87. doi: 10.30476/ijms.2023.96892.2855
Shokripour, Mansoureh, Hosseini, Seyed Ehsan, Omidifar, Navid, Mokhtari, Maral, Safaei, Akbar. Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran. سامانه مدیریت نشریات علمی, 1402; 49(2): 77-87. doi: 10.30476/ijms.2023.96892.2855

Cytogenetic, Clinical, Hematologic, Demographic, Immunohistochemical, and Flow Cytometry Characteristics of Patients with Plasma Cell Neoplasm in Five Years: A First Report from Iran

Iranian Journal of Medical Sciences
مقاله 2، دوره 49، شماره 2، اردیبهشت 2024، صفحه 77-87    اصل مقاله (336.6 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2023.96892.2855
نویسندگان
Mansoureh Shokripour1؛ Seyed Ehsan Hosseini2؛ Navid Omidifar* 2، 3؛ Maral Mokhtari2؛ Akbar Safaei2
1Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: The aggregation of clonal plasma cells causes plasma cell neoplasms, which vary in severity and clinical outcomes. The present research focused on the epidemiological, clinical, immunologic, and cytogenetic characteristics of plasma cell neoplasms. 
Methods: In this five-year retrospective cross-sectional study, demographic information such as age and sex, calcium elevation, renal insufficiency, anemia, and bone lesion (CRAB) characteristics, as well as laboratory data including bone marrow and peripheral blood film results, immunohistochemistry, flow cytometry, and cytogenetic study outcomes were collected at Shiraz University of Medical Sciences, Shiraz, Iran. The collected data were analyzed using SPSS Statistics software (version 20.0). Descriptive statistics were reported as numbers, percentages, and mean±SD.
Results: 417 newly diagnosed plasma cell neoplasm patients were confirmed by bone marrow or other tissue biopsy tests. 279 patients were men (66.9%). The most prevalent age group was 60-64 years old (18.46%). Plasma cell myeloma (PCM) affected 355 (85.13%) patients, while monoclonal gammopathy of undetermined significance (MGUS) affected 6 (1.43%) patients. Solitary plasmacytoma was seen in 56 (13.42%) patients. At the time of diagnosis, 119 (33.52%) of 355 PCM patients were asymptomatic, whereas 236 (66.47%) patients had at least one CRAB symptom, 55 (15.49%) had two or more, and 14 (3.94%) had three or more. There were 7 (1.97%) cases of amyloidosis. Cytogenetic abnormalities were found in 51.28% (40/78) of the patients. Twenty-one individuals (52.5%) were hyperdiploid with multiple trisomy, while 19 (47.50%) were not. 
Conclusion: When diagnosed, Iranian PCM patients might have more advanced disease. PCM was more prevalent in young adults, and hyperdiploid was the most common cytogenetic finding in this investigation.

تازه های تحقیق

Mansoureh Shokripour (Google Scholar)

Navid Omidifar (Google Scholar)

کلیدواژه‌ها
Plasmacytoma؛ Multiple myeloma؛ Cytogenetics
سایر فایل های مرتبط با مقاله
مراجع
  1. Buon E, Guang MHZ, Bianchi G. Plasma Cell Neoplasms: an overview. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2018;22:497-506. doi:10.4267/2042/69019
  2. Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4:1221-7. doi: 10.1001/jamaoncol.2018.2128. PubMed PMID: 29800065; PubMed Central PMCID: PMCPMC6143021
  3. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9. doi: 10.3390/medsci9010003. PubMed PMID: 33498356; PubMed Central PMCID: PMCPMC7838784.
  4. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018. doi: 10.1111/ejh.13083. PubMed PMID: 29676004; PubMed Central PMCID: PMCPMC6195866.
  5. Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56. doi: 10.1038/s41408-020-0323-4. PubMed PMID: 32404891; PubMed Central PMCID: PMCPMC7221083.
  6. Jurczyszyn A, Hutch R, Waszczuk-Gajda A, Suska A, Krzanowska K, Vesole DH. Monoclonal gammopathies of undetermined significance and smoldering myeloma. Acta Haematologica Polonica. 2020;51:193-202. doi: 10.2478/ahp-2020-0035.
  7. Jeryczynski G, Krauth M-T. Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up. memo-Magazine of European Medical Oncology. 2021;14:76-9. doi: 10.1007/s12254-020-00630-z.
  8. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548-67. doi: 10.1002/ajh.25791. PubMed PMID: 32212178.
  9. Rajkumar SV. Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418-23. doi: 10.1200/EDBK_159009. PubMed PMID: 27249749.
  10. Tang CH, Liu HY, Hou HA, Qiu H, Huang KC, Siggins S, et al. Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiol. 2018;55:136-41. doi: 10.1016/j.canep.2018.06.003. PubMed PMID: 29957398.
  11. Jalaeikhoo H, Sharifzadeh M, Rajaeinejad M, Keyhani M, Zokaasadi M. Retrospective Analysis of 345 Multiple Myeloma Cases: An Investigation from 2 Institutions. Arch Iran Med. 2018;21:412-7. PubMed PMID: 30221532.
  12. Nakaya A, Kohara T, Shibayama H, Onda Y, Kanda J, Kaneko H, et al. Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. Int J Hematol. 2020;112:435-8. doi: 10.1007/s12185-020-02996-6. PubMed PMID: 32959221.
  13. Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et al. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep. 2017;9:6887. doi: 10.4081/hr.2017.6887. PubMed PMID: 28286629; PubMed Central PMCID: PMCPMC5337823.
  14. Cei M, Ferretti A, Mumoli N. Patients with very severe anemia: a case series. Rev Bras Hematol Hemoter. 2017;39:285-7. doi: 10.1016/j.bjhh.2017.02.001. PubMed PMID: 28830613; PubMed Central PMCID: PMCPMC5567414.
  15. Ajise OE, Roshal M, Wang L, Sukhram GN, Smith KM, Maslak P, et al. Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. Journal of Hematopathology. 2016;9:9-18. doi: 10.1007/s12308-015-0264-1.
  16. Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. Br J Haematol. 2017;177:67-71. doi: 10.1111/bjh.14513. PubMed PMID: 28146275; PubMed Central PMCID: PMCPMC5396308.
  17. Fitzpatrick MJ, Nardi V, Sohani AR. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol. 2022;51:17-30. doi: 10.1007/s00256-021-03754-3. PubMed PMID: 33687521.
  18. Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus. 2017;33:303-15. doi: 10.1007/s12288-017-0822-z. PubMed PMID: 28824230; PubMed Central PMCID: PMCPMC5544653.
  19. Dass J, Arava S, Mishra PC, Dinda AK, Pati HP. Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study. South Asian J Cancer. 2019;8:60-4. doi: 10.4103/sajc.sajc_64_17. PubMed PMID: 30766858; PubMed Central PMCID: PMCPMC6348785.
  20. Lee N, Moon SY, Lee JH, Park HK, Kong SY, Bang SM, et al. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer J. 2017;7:e530. doi: 10.1038/bcj.2017.14. PubMed PMID: 28211888; PubMed Central PMCID: PMCPMC5386332.
  21. Goldman-Mazur S, Vesole DH, Jurczyszyn A. Clinical implications of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematologica Polonica. 2021;52:18-28. doi: 10.5603/AHP.2021.0004.
  22. Hassan H, Szalat R. Genetic Predictors of Mortality in Patients with Multiple Myeloma. Appl Clin Genet. 2021;14:241-54. doi: 10.2147/TACG.S262866. PubMed PMID: 33953598; PubMed Central PMCID: PMCPMC8092627.
  23. Hamdaoui H, Benlarroubia O, Ait Boujmia OK, Mossafa H, Ouldim K, Belkhayat A, et al. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med. 2020;8:e1363. doi: 10.1002/mgg3.1363. PubMed PMID: 32573970; PubMed Central PMCID: PMCPMC7507047.
  24. Safavi M, Safaei A, Monabati A, Hosseini M, Solhjoo F. Conventional Cytogenetic Abnormalities in Plasma Cell Myeloma and Their Prognostic Effect: A Single Center Experience in the Middle East. Middle East Journal of Cancer. 2021;12:219-27.
  25. Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019;41:5-14. doi: 10.1111/ijlh.12882. PubMed PMID: 29971938.
  26. Mayo Stratification for Myeloma And Risk-adapted [Internet]. Therapy Newly Diagnosed Myeloma. c2019. Available from: https://www.msmart.org/s/Treatment-of-Newly-Diagnosed-Myelomav16_Nov19FINAL.pdf.
  27. Baysal M, Demirci U, Umit E, Kirkizlar HO, Atli EI, Gurkan H, et al. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance. Sci Rep. 2020;10:5991. doi: 10.1038/s41598-020-62885-0. PubMed PMID: 32249811; PubMed Central PMCID: PMCPMC7136246.
  28. Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10. doi: 10.1186/s13045-017-0549-1. PubMed PMID: 29338789; PubMed Central PMCID: PMCPMC5771205.
  29. Basavaiah SH, Lobo FD, Philipose CS, Suresh PK, Sreeram S, Kini H, et al. Clinicopathological spectrum of solitary Plasmacytoma: a single center experience from coastal India. BMC Cancer. 2019;19:801. doi: 10.1186/s12885-019-5976-7. PubMed PMID: 31412808; PubMed Central PMCID: PMCPMC6693151.
  30. Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foa R, Petrucci MT. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol. 2016;172:554-60. doi: 10.1111/bjh.13870. PubMed PMID: 26684545.
  31. Ghiassi-Nejad Z, Ru M, Moshier E, Chang S, Jagannath S, Dharmarajan K. Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis. Clin Lymphoma Myeloma Leuk. 2019;19:310-9. doi: 10.1016/j.clml.2019.01.004. PubMed PMID: 30878315; PubMed Central PMCID: PMCPMC6555681.
  32. Jalaeikhoo H, Zokaasadi M, Rajaeinejad M, Keyhani M, Sharifzadeh M. Study of Multiple Myeloma Occurrence in Patients With 5%-10% Bone Marrow Plasma Cells: A Case Series Regarding Revised IMWG Diagnostic Criteria. Multidisciplinary Cancer Investigation. 2018;2:30-5. doi: 10.30699/acadpub.mci.2.3.1.
  33. Ono E, Ishii A, Higashi Y, Koita N, Ayaki T, Tanigaki K, et al. Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report. BMC Nephrol. 2021;22:74. doi: 10.1186/s12882-021-02272-7. PubMed PMID: 33639890; PubMed Central PMCID: PMCPMC7916314.
  34. Fonseca GSD, Machado JR, Zago LBR, Reis MAD, Monteiro M, Vito FB. Monoclonal gammopathy of renal significance: case report. Hematol Transfus Cell Ther. 2018;40:86-9. doi: 10.1016/j.htct.2017.11.002. PubMed PMID: 30057977; PubMed Central PMCID: PMCPMC6001933.
  35. Yu XJ, Zhou XJ, Wang SX, Zhou FD, Zhao MH. Monoclonal light chain crystalline podocytopathy and tubulopathy associated with monoclonal gammopathy of renal significance: a case report and literature review. BMC Nephrol. 2018;19:322. doi: 10.1186/s12882-018-1108-x. PubMed PMID: 30419839; PubMed Central PMCID: PMCPMC6233383.
  36. Steiner N, Gobel G, Suchecki P, Prokop W, Neuwirt H, Gunsilius E. Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients. Oncotarget. 2018;9:2344-56. doi: 10.18632/oncotarget.23412. PubMed PMID: 29416776; PubMed Central PMCID: PMCPMC5788644.
  37. Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15:45-59. doi: 10.1038/s41581-018-0077-4. PubMed PMID: 30510265; PubMed Central PMCID: PMCPMC7136169.
آمار
تعداد مشاهده مقاله: 2,571
تعداد دریافت فایل اصل مقاله: 442


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب